Oncology News | pharmaphorum

News

Geron finally brings a drug to market as FDA clears Rytelo

More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.

News

Telix prices $200m IPO in big week for radiopharma financing

Australian radiopharmaceutical specialist Telix has revealed the terms of its planned initial public offering (IPO) in the US, revealing that it hopes to raise $202 millio

News

ASCO: KRAS upstarts set their sights on NSCLC market

There are already two drugs on the market targeting KRAS mutations, for decades considered an undruggable target, but no shortage of drug candidates hoping to follow them.

News

ASCO: Moderna may file melanoma vaccine on phase 2b data

New data from a phase 2b trial of Moderna and MSD’s neoantigen melanoma vaccine may be strong enough to consider filing for accelerated approval before a phase 3 programme

News

ASCO: DREAMM-8 data puts GSK’s Blenrep back on track

GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from the DREAMM-8 trial of the drug in multiple myel

News